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Background: It has been suggested that fructose from natural sources including fruit and 
fruit juice behaves differently in the body than added fructose from processed foods. 
Furthermore, there is inconclusive evidence regarding whether whole fruit and fruit juice 
differ in their ability to satiate, and their effects on appetite post consumption.  
Methods: We conducted a randomised controlled crossover trial, with 64 healthy young 
adults. The three arms of the study included the consumption of whole Royal Gala apples, 
100 % New Zealand apple juice, or a control beverage of glucose or fructose in solution. 
Mean change in acute uric acid concentration and incremental area under the curve were 
measured at baseline, and then 30 and 60 minutes post food consumption. Satiety ratings from 
apple and apple juice were measured using visual analogue scales at baseline, 30 and 60 
minutes post consumption.  
Results: We observed a significant difference in plasma uric acid concentration for all three 
foods at 30-60 minutes, except the glucose monosaccharide beverage. No significant 
difference existed between the uric acid increase from apples (P=0.286) or apple juice 
(P=0.132) and the fructose beverage. However, the apple juice and fructose beverages 
displayed a greater rate of increase than whole apples. Some measures of appetite were 
significantly different between the solid and liquid foods during the first 30 minutes, with 
whole apple more satiating than apple juice.  
Conclusions: Fructose control, whole apple and apple juice displayed the same plasma uric 
acid raising potential. These findings suggest the body treats fructose as fructose, independent 
of the food source. Whole apples were more satiating than apple juice, providing evidence for 
the consumption of whole fruit to be encouraged over fruit juice.  
!
Key words: fructose, uric acid, satiety, apples, apple juice, fruit, intrinsic, natural.   
 iii 
Preface 
The candidate developed the research protocols together with her supervisor Dr Bernard 
Venn, co-supervisor Ph.D. candidate Mr Andrew Reynolds and Master of Dietetics candidate 
Emma Carran.  
 
The effect of fructose from apples, commercially available apple juice and control beverages 
on plasma uric acid concentration and satiety are presented in this thesis. These data are a 
component of a larger set, which includes acute plasma uric acid response to sugar-sweetened 
beverages, changes to blood pressure, and gastrointestinal symptoms experienced on 
consumption of the intervention foods. Genotyping will be undertaken on DNA collected 
during the study, which is not a component of this thesis. Master of Dietetics candidate Emma 
Carran will present data from a commercially available, sugar-sweetened beverage separately.  
 
In partnership with Emma Carran, the candidate shared the responsibility of recruitment, 
dietary instruction, procurement of test foods, food preparation, participant attendance, data 
collection and laboratory analysis. The candidate was primarily responsible for the design of 
the satiety and gastrointestinal questionnaires, for data entry, and collating the results.  
 
In order to standardise portion size, the fructose content and sugar profiles of the test foods 
(Royal Gala apples, and commercial 100 % apple juice) were analysed by Cawthron Institute 
Laboratories Ltd, Nelson, New Zealand. All other analyses were carried out by the candidates 
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Introduction  
It has been suggested the free fructose present in fruit does not exert the same adverse effects 
on blood uric acid production and subsequent gout risk as fructose added to processed food in 
the form of sucrose or high fructose corn syrup (HFCS) (1-3), although there is a popular 
view that free fructose behaves the same as added fructose within the body therefore should 
be avoided. Extensive research into the effects of a high fructose diet, particularly the effect 
of HFCS use in the US has observed an association with metabolic diseases such as gout (3-
5). To date, there are limited trials investigating the effects of free fructose from natural food 
sources, including fruit and fruit juice at ‘realistic’ levels, and subsequent uric acid 
production. Inconclusive results from testing excessive doses of fructose on uric acid 
concentration and satiety have arisen from previous work with few participants, or from 
prospective cohort studies (3, 4, 6-8). 
 
Prospective cohort studies have observed an association between added fructose and the risk 
of disease associated with the metabolic syndrome (gout, cardiovascular disease and diabetes) 
(3, 4, 9, 10). The aforementioned diseases are highly relevant in Western society and to New 
Zealand (11-14). Previous studies have observed that uric acid increases with fructose doses 
exceeding 60-80 g per day from fruit (15, 16). Other studies have examined the physiological 
response to fructose in amounts well above typical intake (200 g) (6-8). In New Zealand, it 
was determined adults consume approximately 39-49g fructose per day (17), with fruit 
contributing 18 % to the total sugar intake of the adult New Zealand diet (17), which is a 
lower amount than commonly tested doses of fructose (18). Less than 100 g per day has been 
suggested to have minimal effects and might instead be beneficial (18).  
 
Given that fruits contain fructose, which has perceived negative effects but are recommended 
as part of a balanced diet (2), it is important to determine if the fructose from fruit has 
negative health outcomes. Whole apples have a high free fructose to sucrose ratio when 
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compared to other fruits (19) and are the second most popular fruit consumed by New 
Zealanders, after bananas (20). It is also important to consider fruit as a whole food, instead of 
focussing solely on fructose content. 
 
Fruit juice is considered by some as a greater source of nutrients present in fruit and a more 
convenient means of consuming these nutrients (21). Liquid foods have also been reported to 
result in greater blood glucose and insulin response (22, 23) and be less satiating than whole 
foods, such as whole fruit (23-25). Mechanisms by which whole fruit may be considered more 
satiating include the presence of fibre, requiring greater mastication and inducing gastric 
distension during the a cephalic phase, suspending the hunger response (26). Fibre may also 
delay absorption of nutrients in the small intestine (26).  
 
The consumption of natural fructose sources (fruit and fruit juice with no added sweetener) 
has not been tested in realistic amounts in a randomised controlled trial. Consequently, it is 
not known to what extent this amount of fructose from these sources will raise the 
concentration of uric acid, if at all. It is important to determine the effect of a realistic fructose 
dose, as it is likely results studies investigating excessive fructose consumption have little 
relevance to public health policy, as daily fructose consumption by the population is likely to 
be less (18). Increasing our understanding on this topic may allow for more targeted advice in 
the prevention and management of gout and diseases associated with hyperuricemia.  
 
The consideration of uric acid response to apples and apple juice enabled data collection on 
the second objective of this research, satiety from the consumption of apples versus apple 
juice.  Satiety is of interest, as the satiating properties of whole fruit in comparison to fruit 
juices (with no added sugar) is further evidence to promote the consumption of whole fruit 
rather than fruit alternatives. Increased satiation from the consumption of whole fruit if 
observed, provides a logical limiting factor to the amount of fructose consumed from natural 
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sources in any one sitting. This randomised controlled crossover trial was designed to assess 
the acute uric acid response to realistic amounts of fructose from apples and apple juice in 
comparison with free-monosaccharide beverages. In addition, we aimed to document any 
differences in satiety between whole apple and apple juice, as a secondary outcome, given 
that both foods provide more to the diet than just fructose. 
!  
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Literature Review  
1.1 Methodology of literature review  
The literature gathered for this review was identified using the online databases: Medline via 
Ovid, Science Direct and Pubmed. Keywords used in searches included ‘fructose’, ‘uric acid’, 
‘apples’ ‘fruit’ and ‘satiety’. The references of articles identified in our online search were 
inspected for further articles not yet captured within our search criteria. Relevant trials were 
randomised and controlled with human participants.  
 
1.2 Introduction 
Fructose has a marred reputation largely due to its growing prevalence in the westernised diet, 
in line with the population’s increasing body mass index (BMI) and rate of non-
communicable diseases. The over consumption of fructose from sugary beverages and 
processed foods corresponds to the increasing prevalence of metabolic syndrome. It is 
branded as a leading contributor to the Western obesity epidemic and related diseases, of 
which there is no stand-alone cause. Fructose consumption has also been linked with 
hyperuricemia, a risk factor for the incidence of gout (2, 3, 27, 28). Whether the source is high 
fructose corn syrup (HFCS) or the more prevalent sucrose in the New Zealand diet, the 
presence of fructose in processed food is likely contributing to rising obesity rates (5, 29).   
 
A correlation between gout, and chronically high uric acid levels (hyperuricemia), and 
fructose has been observed in prospective studies after the consumption of substantial 
amounts of added fructose, but not with fruit consumption (3, 4). Habitual fructose 
consumption coupled with genetic susceptibility is suggested to be a contributing factor to the 
increasing prevalence of gout in the population (30, 31), particularly in those of M!ori and 
Pacific Island ancestry (13, 30). Hyperuricemia has been linked to symptoms of the metabolic 
syndrome, including overweight and obesity (4, 5, 27). During 2006, it cost the New Zealand 
!
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The hydroxyl and either the aldehyde or the ketone functions of mono-
saccharides can likewise react intramolecularly to form cyclic hemiacetals
and hemiketals (Fig. 8-3). The configurations of the substituents of each
carbon atom in these sugar rings are conveniently represented by their
Haworth projections, in which the heavier ring bonds project in front of
the plane of the paper and the lighter ring bonds project behind it.
A sugar with a six-membered ring is known as a pyranose in analogy
with pyran, the simplest compound containing such a ring. Similarly, sugars
with five-membered rings are designated furanoses in analogy with furan:
The cyclic forms of glucose and fructose with six- and five-membered rings
are therefore known as glucopyranose and fructofuranose, respectively.
Cyclic Sugars Have Two Anomeric Forms. When a monosaccharide
cyclizes, the carbonyl carbon, called the anomeric carbon, becomes a
chiral center with two possible configurations. The pair of stereoisomers
that differ in configuration at the anomeric carbon are called anomers. In
O O
Pyran Furan
222 | Chapter 8 Carbohydrates
! Figure 8-3 | Cyclization of glucose and fructose. (a) The linear form of 
D-glucose yielding the cyclic hemiacetal !-D-glucopyranose. (b) The linear form of 
D-fructose yielding the hemiketal "-D-fructofuranose. The cyclic sugars are shown














































































































government over 623.9 million, or 4.4% of total health care expenditure (15.4 billion) to treat 
obesity-related conditions (32), to which hyperuricemia contributes.  
 
This review considers the issues surrounding an increase in intake of fructose consumption 
with gout and elevated uric acid, as health outcomes and the respective relationship with 
fructose from fruit and fruit juice. Popular media sites, widely read by the public, often 
portray fructose in a negative light (33). Perceptions of the public may be that fruits provide 
unnecessary calories or sugar, without recognising a valuable source of vitamins and 
minerals, or other proven health benefits (2, 34-37).  
 
Popular diets and some researchers often recommend minimising fruit consumption, as they 
are well-known sources of fructose, which has been labelled a ‘bad sugar’ (4, 38, 39). The 
rationale behind these claims includes the potential to cause fat deposition, irregular eating 
patterns or interference with satiation (39-41). These claims may cause confusion amongst the 
public; given New Zealand public health strategies encourage people to include adequate 
servings of fruit and vegetables into their diet (42, 43). Individuals may choose to restrict or 
avoid fruit as recommended by some health promoting websites (44). As society continues to 
look for easy strategies for weight loss, these conflicting messages may become detrimental to 
the credibility of the advice given by health professionals.  
1.3 Fructose structure 










Figure 1. structure of D-f uctose in linear form (45) 
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1.4 Fructose Absorption 
1.4.1 Absorption in the small intestine 
Fructose is absorbed from the small intestine through facilitated diffusion (46) in a similar 
process to glucose, predominantly utilising the transport proteins Glucose Transporter 5 
(GLUT 5) and Glucose Transporter 2 (GLUT 2) (47). While GLUT 5 was traditionally 
identified as a basal membrane glucose transporter, it has a higher affinity for fructose (46, 
47) and has been observed within many cells (48). Glucose Transporter 2, which has a low 
affinity for fructose, transports the sugar out of the enterocyte, and into liver but to what 
extent is undetermined (47-50). Glucose transporters 7,8 and 12 may also transport fructose 
(47). Fructose absorption is higher if glucose is present, when absorbed in the form of 
sucrose, producing a ‘synergistic effect’ (51). Isotope tracer studies were used to quantify this 
effect, where it was determined the rate of fructose oxidation increased when ingested with 
glucose (51). This finding suggests fructose transport may be glucose-dependent (46, 48). 
!
1.5 Fructose Metabolism  
Fructose is primarily metabolised in the liver (45). The monosaccharide undergoes 
phosphorylation through the action of fructokinase (keto hexokinase) and adenosine 
triphosphate (ATP) (52, 53). Fructose it is phosphorylated at the first carbon forming fructose 
1-phosphate (fructose + ATP → fructose 1-phosphate) (52, 53). This process occurs rapidly 
as fructokinase has a high affinity for fructose (52, 54) and occurs faster than glucose 
phosphorylation (52).  
 
Secondly, fructose 1-phosphate is cleaved by aldolase B (fructose 1-phosphate aldolase), to 
dihydroxyacetone phosphate and glyceraldehyde, which are glycolysis intermediates (54). To 
enter the glycolysis pathway both intermediates must undergo further phosphorylation (54). 
Dihydroxyacetone phosphate is phosphorylated to glyceraldehyde 3-phopshate by the enzyme 
!
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triose phosphate isomerase (Figure 2) (55). Glyceraldehyde is also converted to 
glyceraldehyde 3-phosphate through phosphorylation by triose kinase and ATP (Figure 2) 
(55). These units enter the gluconeogenesis pathway to form glucose (46).  
 
This process is possible in multiple tissues, as fructokinase is observed in the liver, intestine 
and kidneys (46). Hexokinase, the equivalent fructose enzyme is present in muscle cells, 
allowing fructose metabolism to proceed in many tissues if ingested fructose concentrations 
are high (45) (Figure 2). In muscle, hexokinase phosphorylates fructose at position C-6 
forming fructose 6-phosphate, which is an intermediate of glycolysis and can enter into the 
pathway, requiring no further modification (55).  
 
 




1.6 Uric acid production 
Previous work has determined the ingestion of fructose can result in the production of uric 
acid (3, 4), which in high concentrations is classified as hyperuricemia. Excess uric acid 
formation occurs with the catabolism of adenine nucleotides ATP, adenosine diphosphate 
(ADP), and adenosine monophosphate (AMP), (AMP + ATP " 2 ADP) (53, 54, 56). This 
process was determined with a 50 g intravenous infusion of fructose (53). Due to the rapid 
phosphorylation of fructose, which depletes ATP and Pi, metabolism cannot continue (54). A 
depletion of ATP and organic phosphate (Pi) leads to the degradation of AMP (53). 
Adenosine triphosphate and Pi inhibit deaminase and 5’-nucleotidase; consequently, AMP is 
converted to inosine monophosphate (IMP) when inhibition is no longer present (53, 54). 
 
 Inosine monophosphate is converted to inosine by the dephosphorylation by 5’-nucleotidase 
(54). Inosine is the precursor of uric acid, which is phosphorylated to hypoxanthine, then 
oxidised to xanthine (45). Xanthine is further oxidised to uric acid (45). As humans do not 
possess the enzyme uricase, uric acid is the end product of purine metabolism and is excreted 
via the urine (45, 57, 58). The absence of uricase increases the likelihood of the development 
of hyperuricemia (54, 57, 58). Nonetheless, not all people with hyperuricemia progress to 
gout (59, 60), suggesting there are other genetic mechanisms involved (31). 
 
Studies investigating antioxidant status after fruit consumption observed an increase in uric 
acid concentration after consuming fruit juice (16) or fruit (15). Thirty-six grams of fructose 
from apples induced a modest but non-significant, transient rise in plasma urate concentration. 
Sixty-four grams of fructose in the form of 1000 g apples and a fructose beverage induced a 
31 µM (µmol/L) rise in urate concentration. No significant difference was observed between 
the food sources of fructose (15). However, this study did not include the sucrose 
concentration of the apples in the total fructose calculation, potentially underestimating the 
concentration of fructose (15). In a longer term study conducted in the 1950’s it was 
!
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determined there were no detrimental effects of eating a fruit diet supplemented with nuts and 































Figure 3. The relationship between fructose metabolism and the formation of uric acid in the liver.  
P: phopshate, AMP: adenosine monophosphate, ADP: adenosine diphosphate, ATP: adenosine 
triphosphate, Pi: organic phosphate, GMP: guanosine monophosphate, PRPP, 5-phosphoribosyl-1-
pyrophosphate, IMP: inosine monophosphate (54) 
 
1.7 Sources of fructose 
1.7.1 Intrinsic  
Fructose exists intrinsically in foods as a free monosaccharide, termed ‘free fructose’ or 
bound to glucose in a disaccharide as sucrose (55). Glucose and fructose are bonded through a 
glucosidic alpha 1-2 bond, at C1 and C2 respectively (45) (Figure 4). Fructose is present in 
processed foods but also naturally occurs in food such as fruit, honey or some root vegetables 
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tose do not raise the plasma uric acid concentration (133). Pa-
tients suffering from gout arc more sensitive to fructose admin-
istration than are normal subjects, as are diabetics (130). These
results apply to fructose administered parenterally, but is it pos-
sible to increase blood uric acid concentrations when fructose is
consumed orally? The effect of feeding fructose at a dose of 1 g!
kg body wt was studied in healthy subjects, in patients with gout,
and in children of parents with gout (78). Hyperunicemia oc-
curred in all groups but it was more marked and prolonged in
those subjects, or offspring of parents, with gout. Subjects con-
suming higher than  18% of their energy intake as sucrose (ic,
9% as fructose) showed significant increases in serum uric acid
(130). These results suggest that the average intake of fructose
or sucrose in a mixed diet is on the borderline for provoking
hyperunicemia in normal individuals. Note that gouty patients do
have lower serum uric acid conccntrations when fed lower-fruc-
tose diets; even healthy individuals may be at risk of hyperuni-
cemia when consuming a diet high in fructose.
Pathways of adenine nucleotide catabolism and biosynthesis
To understand the mechanism of the hyperunicemic effect of
fructose a knowledge of puninc nucleotide metabolism and its
regulation is necessary. Adenylate kinase maintains equilibrium
between the adenine nucleotides ATP, adenosinc diphosphate
(ADP), and adenosine monophosphate (AMP) (Fig 2). Thus, all
three adenine nuclcotides are able to be degraded and formed via
AMP. However, as with many other common metabolites, the
pathway of degradation of adenine nucleotides is not the simple
reverse of the pathway of biosynthesis. In the degradative path-
way, inosine monophosphate (IMP) is formed from AMP by the
action of AMP deaminase. Phosphate is then removed by 5’-
nucleotidase to form inosine. Alternatively, inosine may be
formed from AMP via adenosinc but experiments in isolated he-
patocytes (31) have indicated that this is not as important a route
for AMP degradation as that via IMP. In addition, the reaction
catalyzed by AMP deaminase appears to be the rate-limiting step
in the breakdown of hepatic adeninc nucleotides (134-136), and
Pi at normal intracellular concentrations is an important inhibitor
of this enzyme. Inosinc is broken down to uric acid via hypo-
xanthine and xanthinc. In humans and other primates this is the
end product of purinc metabolism and is excreted as such, but
other mammals possess the enzyme unicase, which allows further
oxidation to the much more soluble allantoin. A consequence of
the absence of unicase in humans is the occurrence of gout, which
is associated with hypcruniccmia.
IMP is also the first formed punine nucleotide in the pathway
of de novo synthesis from nibose 5-phosphate. This pathway in-
volves no less than 1 1 separate steps (137). Of these, only the
first two need to be mentioned because they catalyze the rate-
controlling reactions, both of which are held in check by a feed-
back regulation because of high concentrations of puninc nude-
otides. In addition, 5-phosphonibosyl-1-pyrophosphatc (PRPP),
the product of the first reaction in the pathway is an allostenic
activator of the second reaction in the pathway catalyzed by
PRPP glutamyl amidotransferase (Fig 2).
Mechanism underlying the hyperuricemic action of fructose
The essential finding that led to the explanation as to why
fructose administration caused increased uric acid formation was
the observation that it was accompanied by a sharp fall not only
76lS
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FIG 2. The relationship between fructose metabolism and uric acid
formation in the liver. P. phosphate; AMP, adenosine monophosphate:
ADP, adenosine diphosphate; ATP, adenosine triphosphate; Pi, organic
phosphate; GMP, guanosine monophosphate; PRPP, 5-phosphonibosyl-
1-pyrophosphate; IMP, inosine monophosphate.
in hepatic AlT concentration but also in total adeninc nucleotides
(76). The reason for this became apparent when it was shown
that fructosc-1-phosphatc accumulated and Pi concentrations fell
(27). Thus, the sequence of events after fructose administration
involves rapid phosphorylation of the sugar to fructose-1-phos-
phate because of the high activity of fructokinase. This leads to
depletion of ATP due to inhibition of oxidative phosphorylation
of ADP because of a shortage of Pi sequestered in fructose-i-
phosphate. The lowering of AlP concentration is also assisted
by the activity of tniokinase in utilizing Al? in the phosphory-
lation of glyceraldehyde to glyccraldehyde-3-phosphatc. The de-
pletion of Pi and ATP leads to the removal of the allostenic in-
hib tion on the enzymes that degrade AMP, respectively, AMP
deaminase and 5’-nuclcotidase. There is a rise in inosinc con-
centration that leads to increased formation of uric acid with de-
pletion of the total adenine nucleotide pool.
The depletion of adenine nucleotides also leads to stimulation
of the pathway of punine nucleotide synthesis as a feedback re-
action (Fig 2). The lowering of the concentration of adenine nu-
cleotides removes the allostenic inhibition of the first two steps
in the pathway catalyzed by PRPP synthetase and PRPP glutamyl
amidotransferase. The production of PRPP acts as a further ac-
tivator of PRPP glutamyl amidotransferase, leading to IMP syn-
thesis. If 5’-nucleotidase is still active, IMP will be degraded to
uric acid rather than converted to AMP. In this way the initial
production of uric acid from the adenine nuclcotidc pool is aug-
mented by dc novo synthesis.

























Table 1. Sugar composition of some common fructose containing foods (g/100g (19, 63) 
!
Fructose containing foods Total Fructose (g) Sucrose (g) Glucose (g) Total Sugars (g) 
Apple raw, with skin* 5.90 1.86 2.71 10.48 
Banana, raw* 4.85 2.39  
 
4.98 12.23 
Fruit juice, apple*  5.73 1.26  
 
2.63 9.62 
Carbonated beverage, sprite  
(HFCS sweetened) + 
 
6.25 0.00 4.14 10.42 
Carbonated beverage, sprite*  
 
5.19 0.65 3.13 8.98 
* (19), + (63) 
 
Some fruits contain larger concentrations of fructose than others such as apple, pears and 
grapes, or a higher ratio of fructose to glucose (19). In the New Zealand diet fruit contributes 
13 % of total sugar intake in 2-18 year olds, and 18 % of total sugar intake in adults, being the 
second highest source of total sugar (17, 43).  
 
1.7.2 Fruit juices 
Processed forms of fruit i.e. natural fruit juices compile other sources of fructose and include 
apple juice. Around 60% of the calories available in apple juice may be from fructose (5). 
Apple juice intake and the effects of a fructose load on subsequent uric acid levels are of 
interest in this thesis. Fruit juice is different to fruit drinks, which contain concentrate and 
added sugar rather than pure fruit juice (21). This thesis will investigate 100 % fruit juice.  
 
endopeptidases cleave amino acid residues from polypeptides (Section 5-3B).
NMR measurements are also invaluable in determining both sequences
and conformations of polysaccharides.
A | Lactose and Sucrose Are Disaccharides
Oligosaccharides containing three or more residues are relatively rare,
occurring almost entirely in plants. Disaccharides, the simplest polysaccha-
rides, are more common. Many occur as the hydrolysis products of larger
molecules. However, two disaccharides are notable in their own right.
Lactose (at right), for example, occurs naturally only in milk, where its con-
centration ranges from 0 to 7% depending on the species (Box 8-1).
The systematic name for lactose, O-!-D-galactopyranosyl-(1n4)-D-glu-
copyranose, specifies its monosaccharides, their ring types, and how they
are linked together. The symbol (1n4) combined with the ! in the prefix
indicates that the glycosidic bond links C1 of the ! anomer of galactose
to O4 of glucose. Note that lactose has a free anomeric carbon on its glu-
cose residue and is therefore a reducing sugar.
The most abundant disaccharide is sucrose,
the major form in which carbohydrates are transported in plants. Sucrose is
























































Section 8-2 Polysaccharides | 227
BOX 8-1 BIOCHEMISTRY IN HEALTH AND DISEASE
Lactose Intolerance
In infants, lactose (also known as milk sugar) is hydrolyzed by the
intestinal enzyme !-D-galactosidase (or lactase) to its component
monosaccharides for absorption into the bloodstream. The galac-
tose is enzymatically converted (epimerized) to glucose, which is
the primary metabolic fuel of many tissues.
Since mammals are unlikely to encounter lactose after they
have been weaned, most adult mammals have low levels of
!-galactosidase. Consequently, much of the lactose they might
ingest moves through their digestive tract to the colon, where
bacterial fermentation generates large quantities of CO2, H2, and
irritating organic acids. These products cause the embarrassing and
often painful digestive upset known as lactose intolerance.
Lactose intolerance, which was once considered a metabolic dis-
turbance, is actually the norm in adult humans, particularly those of
African and Asian descent. Interestingly, however, !-galactosidase
levels decrease only mildly with age in descendants of populations
that have historically relied on dairy products for nutrition through-
out life. Modern food technology has come to the aid of milk lovers
who develop lactose intolerance: Milk in which the lactose has
been hydrolyzed enzymatically is widely available.
systematic name for sucrose, O-"-D-glucopyranosyl-(1n2)-!-D-fructofura-
noside, indicates that the anomeric carbon of each sugar (C1 in glucose and
C2 in fructose) participates in the glycosidic bond and hence sucrose is not
a reducing sugar. Noncarbohydrate molecules that mimic the taste of
sucrose are used as sweetening agents in foods and beverages (Box 8-2).
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1.7.3 Added sugars 
Added sugars or free sugars from extrinsic sources are added to food during production and 
contribute to fructose intake in the form of sucrose, free fructose or HFCS (17, 36) are added 
to food during production and contribute to fructose intake (62, 64).  
 
1.7.4 High fructose corn syrup 
A large proportion of fructose intake is provided by foods containing HFCS, which has 
replaced the use of sweeteners from sugar cane and beets (62). The USA is the primary 
consumer of HFCS, but its use as a sweetener in foods is increasing worldwide (65). High 
fructose corn syrup is formed through the hydrolisation of corn starch, which converts glucose 
molecules into fructose (62). High fructose corn syrup is a ratio of fructose to glucose 
monosaccharides (62, 64). High fructose 55 is a ratio of 55:45 (fructose: glucose) and is the 
most commonly used sweetener in soft drinks and sweetened beverages in the US (62, 64).   
 
1.7.5 Sugar sweetened beverages 
Sugary beverages appear to be the primary contributor of excess fructose and free sugar in the 
population (17, 66). Excess sugar consumption is speculated to contribute to an increase in 
BMI and prevalence of Type 2 Diabetes Mellitus (T2DM), cardiovascular disease (CVD), 
hypertension (HTN), metabolic syndrome, non-alcoholic fatty liver disease and gout within 
the New Zealand population (4, 10, 12, 28, 67-69). The New Zealand Beverage Guidance 
Panel aims to minimise the consumption of sugar-sweetened beverages, to aid New Zealand 
to become sugary beverage free by 2025 to minimise the risk of related diseases (70, 71). 
 
1.8 Sugars and fructose consumption in New Zealand 
Sucrose is the primary added sugar during food manufacture in Australia and New Zealand 
(17). Although sugar-sweetened beverages in New Zealand do not contain HFCS, a 
correlation between gout prevalence and the habitual consumption of sugar-sweetened 
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beverages has been observed here (69). The total fructose amount consumed from the New 
Zealand diet can be estimated using results from the Adult Nutritional Survey (ANS) 2008/09 
(17), by adding free fructose to half of the median usual daily intake of sucrose presented in 
the ANS findings (17). Consequently, total median intake of fructose for males and females 
was determined to be 49.1g and 39.3g respectively (17). While this observational data can 
describe the current intake, the minimum level of fructose tolerated by the liver before 
adverse effects occur is still largely unknown. There is limited research investigating realistic 
habitual fructose consumption and gout risk.  
 
The Ministry of Health predicts that 29% of carbohydrate consumed within the New Zealand 
adult diet is comprised of free sugars in the form of non-alcoholic sugary beverages (43). This 
is a problem due to the high energy density, low nutrient value and the aforementioned 
negative health effects associated with the consumption of sugary beverages (72).  
 
In New Zealand popular sugar sweetened beverages including sugary beverages (carbonated, 
energy or sports drinks) contain approximately 9.9-10.2 g of total sugar per 100ml, and can 
contribute approximately 500 kilojoules (kJ) to a person’s daily energy intake with just one 
glass (73). Half is presumed to be fructose if the product is sweetened with sucrose, or a 
higher proportion if sweetened with HFCS.  
!
1.9 Fructose and health 
1.9.1 Perceived health benefits of fructose 
Fructose was previously recommended as an alternative sweetener for non-insulin dependent 
diabetic patients (51, 54), as it is claimed to not induce a postprandial insulin response (51) 
and to significantly improve glycaemic control in non-insulin dependent diabetic patients 
(74). The production of uric acid from fructose consumption has known pathogenic effects. 
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An increase in antioxidant status of participants ingesting fructose has been determined and 
attributed to an increase in serum uric acid concentration (7, 8, 15, 16, 75).  
 
1.9.2 Fructose health claim 
The reported reduction of post-prandial glycaemic response prompted the European Food 
Safety Authority (EFSA) to provide guidelines for fructose use in food and beverages (76). 
The resulting policy allows a health claim to highlight the health benefits of fructose on the 
front of foods and beverages containing the sugar (76). The EFSA panel states “consumption 
of fructose leads to a lower blood glucose rise than the consumption of sucrose or glucose,” 
(76) despite EFSA’s acknowledgement that over-consumption of fructose may lead to the 
development of metabolic abnormalities (76). In addition, EFSA stated there was no evidence 
to suggest an upper intake limit of fructose intake (77). This policy may allow the food 
industry to direct its marketing efforts to those individuals aiming to reduce their blood 
glucose levels.  
!
1.10 Diseases associated with excess fructose consumption 
1.10.1 Gout  
Hyperuricemia is the primary risk factor for gout and is the primary disease associated with 
fructose consumption (3). It occurs when serum urate levels induced by diet rise above the 
saturation concentration in body fluids (approximately 0.4mmol/L (400 µmol/L)) (78). A 
single dose of fructose may acutely elevate uric acid, but the habitual intake of fructose and 
the related physiological processes is suggested to determine chronically saturated uric acid 
levels (hyperuricemia) and possibly gout (4). Gout is characterised by the crystallisation of 
mono sodium urate at saturation levels in the joints (31, 79), which causes painful episodes or 
‘attacks’ of symptoms similar to that of arthritis (78). ‘Gout attacks’ occur in the peripheral 
joints or extremities, with severe pain, swelling, and inflammation (60). Without treatment, 
gout can permanently damage the joint and kidney tissues (79). When combined with other 
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risk factors, such as hypertension and diabetes, hyperuricemia may increase the risk of heart 
disease and kidney failure (60, 80). Those with a family history of gout were observed to be 
more susceptible to the uric acid increasing mechanism of fructose and gout development, 
compared to those without a family history of gout (81). 
 
Worldwide prevalence of gout 
The increasing prevalence of gout is not only confined to New Zealand, but has occurred 
worldwide particularly in Western countries (82, 83). Given the detrimental nature of gout as 
a disease, further research is required into the causality of specific risk factors in Western 
society. The number of countries adopting a westernised diet makes this a pertinent issue. 
Gout is predominantly genetic, although environment or diet is said to play a part, as ‘trigger 
foods’ can induce a gout ‘attack’. Foods that commonly cause gout attacks contain purines; 
present within the genetic fraction of food including meat and seafood (84). Purines are the 
basic structure of DNA, which when metabolised within the human body release uric acid 
into the bloodstream (45).  
 
Gout prevalence in New Zealand 
The crude prevalence of gout is 2.69% in New Zealand, which is one of the highest rates 
worldwide (13, 14, 85). Gout is most common in older men and postmenopausal women (14, 
86) (87, 88), particularly those of Pacific, M!ori, or New Zealand European ancestry in 
descending order (13, 14). It is predicted approximately 25% of elderly men (>65 years) of 
M!ori and Pacific peoples are at risk of gout (13). This number may be increasing when 
compared to the prevalence of gout in 1978 (89).  
 
Genetic research suggests the difference in urate response between ethnicities in New Zealand 
is likely due to variants in the gene SLC2A9, which controls the expression of the GLUT 9 
transporter (SLC2A9). GLUT 9 is observed in the renal tubule and is responsible for 
reabsorbing glucose and fructose (90). SLC2A9 was determined to be responsible for urate 
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reabsorption, with many other urate transporters, at the same site along (31, 90). Genetic 
variants of this gene may result in an increase or decrease in the rate of uric acid excretion 
(90). M!ori and Pacific peoples are speculated to be at risk of gout because they are 
genetically susceptible to hyperuricemia (13, 14, 31). 
 
1.10.2 Obesity 
Unlike glucose, fructose consumption does not induce an insulin response (51); therefore, it is 
speculated fructose has no mechanism by which satiety is regulated post prandial ((41, 91). 
Thus, the interaction between the hormones insulin and leptin, which together regulate food 
intake and body weight, suggests an underlying relationship between fructose and weight gain 
(41). Previous trials suggest that large doses of glucose and fructose both induce weight gain 
in participants (92). It is inconclusive whether fructose is more obesogenic than glucose.  
 
1.11 Satiety and fructose  
1.11.1 Solid versus liquid foods and satiety 
It has been determined it is relatively easy to consume large amounts of energy through the 
consumption of sugary beverages. Over-consumption may occur through the lack of 
compensation for calories ingested during successive meals (93, 94). It was observed that 
participants consumed greater energy when a beverage was consumed with solid foods (25, 
93, 95), suggesting sugary beverages do not induce a strong satiety response (25, 94-96).   
 
It is suggested by the World Health Organization (WHO) (97), that excess energy intake from 
sugary beverages is promoted by the lack of fibre, protein and fat, which leads to reduced 
satiation (36). The evidence surrounding satiety after liquid versus solid carbohydrate is 
conflicting and inconclusive (91, 98). Although there is persuasive evidence sugary beverages 
are easy to consume in large amounts compared to solid foods (98).  
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There is evidence that solid fruit is more satiating when compared to fruit juice (25), which 
may provide explanation for why the consumption of sugar-sweetened beverages is associated 
with gout (4, 69). It was observed the ease of consumption was greater when drinking fruit 
juice than whole fruit (25). Physiological factors other than the nutrient content of a beverage 
are said to contribute to a lack of satiation (99). Lack of mastication (100), and decreased 
gastrointestinal transit time, due to the lack of pectin and fructan fibres usually present in 
fruits, may contribute (101, 102). The resulting lack of satiation may contribute to the 
increased consumption of beverages (99, 103, 104) and induce weight gain compared to the 
consumption of whole fruit matched to the sugar content (25). 
!
1.12 Rationale for our research 
There is limited work considering the effects of fruit and fruit juice consumption regarding 
gout risk. Fructose is known to increase plasma uric acid, but limited studies test foods that 
are natural sources of fructose. Our randomised controlled crossover trial is novel, as the 
consumption of realistic servings of natural fructose and its effect on uric acid concentration 
has not been investigated in New Zealand. Due to New Zealand’s high prevalence of gout, 
more information needs to be collected to eliminate the fear of fructose consumption from 
fruit. The magnitude of acute uric acid production after consumption of fruit and fruit juice in 






Aim: To determine the effects of the consumption of Royal Gala apples and commercially 
available 100 % apple juice (with no added sugar) on acute uric acid production, and satiety 
in a cohort of healthy young adults. The intervention includes a “small” and “large” serving of 
apples (205 and 410 grams) and apple juice (170 and 340 millilitres). A second and separate 
objective was to measure participant satiety using visual analogue scales (VAS).  
 
Objective one: To test whether the consumption of natural sources of fructose from common 
fruit and fruit products, in realistic serving sizes, has a significant effect on acute blood uric 
acid concentration, when compared to a pure fructose beverage.  
 
Objective two: To examine the differences between the satiating properties of whole apples 






A randomised controlled crossover trial, which ran over four weeks was undertaken at the 
Department of Human Nutrition, University of Otago, Dunedin, New Zealand, between 
February and March 2015.  
 
1.13 Ethical approval   
The University of Otago Human Ethics Committee (Health) approved this study in November 
2014 (Ethics Committee reference number 14/204) (Appendix A, B). The trial was registered 
with the Australian New Zealand Clinical Trial Registry (ANZCTR:12615000215527). 
 
1.14 Enrollement and participation requirements 
Participants were a convenience sample of University of Otago Human Nutrition students, 
recruited in February 2015. Participants were provided a full study information sheet and 
consent form anytime online before and during the study period. Participants were required to 
provide informed consent before entering the study. Participants were required to be between 
18 and 65 years of age, and to have normal glucose tolerance, defined by the World Health 
Organization as a fasting blood glucose concentration below 5.6 mmol/L (105).  
 
Exclusion criteria were diabetes mellitus, cancer, a digestive condition that may affect the 
absorption of fructose, a recent stroke, and women who were pregnant. A demographic 
questionnaire was used to screen participants for study eligibility (Appendix A). Participation 
involved consumption of an allocated intervention food, providing blood samples for plasma 
uric acid and glucose analysis, and completion of several questionnaires. Ethnographic and 
lifestyle data were collected. A satiety questionnaire was completed at baseline and 30 and 60 
minutes following consumption of the test foods. Blood pressure, height, and weight were 
measured at baseline.  
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1.15 Randomisation 
Seventy-three participants were invited to participate and then randomised into the study 
groups (58 females, 15 males) Figure 1. Participants were block randomised by sex into one 
of the intervention groups to allocate evenly males and females into the three intervention 
arms. For each group, participants were randomised to order and test sessions. Within each 
test session, participants were randomised to staggered attendance times. These times were 
often not adhered to in practice. Randomisation was undertaken by Dr Jill Haszard with 























Invited to participate face to 
face and via email (n= 73) 
Excluded  (n= 0) 
 All participants met inclusion 
criteria  
Analysed  (n= 23) 
!!Excluded from analysis 
(incomplete data set) (n=0)!
Completed both intervention 
sessions (n=21) 
Discontinued intervention 
(withdrawal from study, 
completed only first testing day) 
(n= 2) 
Allocated to control (n=23) 
!!Received allocated intervention  
(n= 19)!
!!Did not receive allocated 
intervention (declined to 
participate) (n= 4)!
Completed both intervention 
sessions (n=21) 
Discontinued intervention 
(withdrawal from study, 
completed only first testing day) 
(n=1) 
Allocated to apple juice group 
(n=22) 
!Received allocated intervention  
(n= 21)!
!!Did not receive allocated 
intervention (declined to 
participate) (n= 1)!
Analysed  (n= 21) 
!!Excluded from analysis 





Allocated to apple group (n=27) 
!!Received allocated intervention  
(n= 23)!
!!Did not receive allocated 
intervention (declined to 
participate) (n= 4)!
Completed both intervention 
sessions (n=18) 
Discontinued intervention 
(withdrawal from the nutrition 
course, completed only first 
testing day) (n=1) 
Analysed  (n=19) 
!!Excluded from analysis 





1.16 Intervention foods 
Apples and apple juice were selected as intervention foods due to their natural fructose 
content, and because they are widely available and accepted foods. Compared to other fruit, 
apples have a high fructose content, of approximately 5.9 grams per 100 grams (19) (Table 
1). The serving sizes provided within the study were designed to represent the normal 
consumption of fruit and fruit juice, to give the study a practical application. Intervention 
foods were purchased from a local supermarket from late February to late March 2015.  
 
Royal Gala apples were chosen as they were in season during the study period. A ‘Mill 
Orchard’ brand of apple juice was chosen, as it contained 100 % apple juice made from New 
Zealand grown apples. The apple juice had no added sugar, preservatives, colours, flavours or 
concentrate (106). The variety of apples within the juice could not be determined as the juice 
is made from a blend of apple varieties (106).  
!
1.17 Control foods 
The control group received a fructose or glucose monosaccharide beverage (4.45 % 
concentration) dissolved in 600 mL of soda water, in random order. A fructose beverage was 
used as a positive control as the fructose monosaccharide is readily absorbed without 
enzymatic degradation (107), or interference from fruit fibres and phytochemicals. A glucose 
beverage was used as a negative control because no rise in plasma uric acid concentration was 
expected, as there is no known pathway by which glucose is converted to uric acid (53, 108).  
 
1.18 Sugar composition analysis  
Cawthron Laboratories Ltd, Nelson, New Zealand, assessed the free fructose, sucrose and 
glucose content of the intervention foods. Analysis occurred during February 2015. The sugar 
content of the foods was quantified to ensure consistency across the study. The fructose 
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amounts of apple and apple juice were matched to the fructose amount provided to 
participants in the control beverages (26.7 grams).  
 
Total fructose was calculated by adding the free fructose and half of the sucrose amount for 
each intervention food. The fructose concentrations of the small servings were set at half the 
fructose concentrations in the large servings. By matching the fructose content of the control 
and large intervention servings, we could directly compare the effects of intervention foods 
against the control beverages. 
 
 Cawthron Laboratories Ltd conducted a second analysis during March 2015 on samples of 
apples and juice consumed during the trial, to ensure the amounts of fructose were 
comparable among intervention foods. Little variation existed between the two samples. Free 
fructose, glucose and sucrose concentrations per 100 g varied by 0.3g, 0.4g, 0.2g respectively 
for Royal Gala apples, and 0g, 0.8g, 0.3g respectively for apple juice. Results from the food 
composition analyses are presented in Table 2 and are attached as appendices (Appendix C). 
!
 







1.19 Amounts administered 
The apple and apple juice intervention groups consumed a small (13.4 grams) serving and a 
large (26.7 grams) serving of fructose in pre-randomised order. Intervention food servings are 
presented in Table 3. The apple group received chopped, and unpeeled whole Royal Gala 
 
 Apple (n=23) 
Apple Juice 
(n=21) 
Free fructose (g/100g) 5.20 7.40 
Fructose from sucrose 
(g/100g) 1.30 0.45 
Total fructose available (g/100g) 6.50 7.85 
Amount of intervention food given 




apples with the stalk, core and seeds removed. Apples were stored in the fridge before the test 
session and removed the morning of the test session.  The apple pieces were covered with 




 Table 3. Large servings of intervention foods containing 26.7 grams of fructose and small 






1.20 Intervention  
The acute effects on circulating uric acid concentration and satiety after consumption of the 
test foods (Royal Gala apples and 100 % apple juice) in comparison with the control 
beverages (glucose and fructose monosaccharides) were examined. Participants presented at 
the test facility twice over a four-week period and were required to fast from 10 pm the night 
before.  
 
Participants were instructed to avoid alcohol and to eat a meal rich in carbohydrates the 
previous night, prior to their allocated study time. Participants were also asked to avoid 
vigorous physical activity; subsequently, it was recommended participants drove or walked 
slowly to the testing facility, then rested, before commencing the study. To survey compliance 
with pre-test instructions, participants were required to fill in a questionnaire regarding their 
alcohol intake, food consumption, and level of physical activity during the 24 hours prior to 




Apple Juice Control (fructose/glucose) 
Small serving 205 g 170 mL - 
Large serving 410 g 340 mL 600 mL 
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were compliant with instructions. The remaining participant’s data were monitored with no 
outliers observed. No adjustment was made for outliers.   
 
Participants were then administered the randomly allocated intervention food, which was to 
be consumed within 10 minutes. During the second visit, participants received the same test 














Week 1 Week 2 Week 3 Week 4 
!
340 ml Apple Juice 
170 ml Apple Juice 
340 ml Apple Juice 
170 ml Apple Juice 
Fructose control Fructose control 
Glucose control Glucose control 
Fructose control Fructose control 
Glucose control Glucose control 
205 g whole apple 
410g whole apple 
205 g whole apple 
410g whole apple 
205 g whole apple 
410g whole apple 
205 g whole apple 
410g whole apple 
340 ml Apple Juice 
170 ml Apple Juice 
340 ml Apple Juice 





1.20.1 Outcome measures  
!
Body Mass Index 
Research assistants trained in anthropometric measurement (ISAK level one accreditation), 
recorded participant heights using a calibrated Holtain Limited Stadiometer. Body weight was 
measured using calibrated Seca Alpha scales (model 770). Participants had removed shoes 
and socks before weight and height measurements were taken. The data were used to 
calculate body mass index (BMI), for each participant using the equation: weight in 
kilograms/height in metres squared (kg/m2).  
!
Blood pressure 
Resting baseline blood pressure was taken using an OMRON digital automatic blood pressure 
monitor (Model Hem-907). The final blood pressure reading was an average of three 
readings.  
!
Uric acid and glucose 
After baseline data capture, participants underwent a 90-minute plasma uric acid and glucose 
response profile on consumption of an apple, apple juice or control beverage. The start time 
of the experiment (Time 0) was the commencement of the consumption of the intervention 
food. Wheat bags were provided to participants to warm their hands to ease blood collection. 
Five hundred µL blood samples were obtained from a single fingertip puncture, using BD 
Microtainer contact activated lancets. Blood samples were collected into BD Microtainers 
coated with the anticoagulant K2EDTA (Appendix E).  
 
Blood glucose was measured over the test period to capture acute changes, induced by the 
intervention foods. Any abnormal glucose concentrations were re-tested. Blood glucose 





Visual analogue scales (VAS) were used to assess hunger, satisfaction, fullness, and 
prospective food consumption ratings induced by the intervention foods (Appendix G). The 
participants completed four VAS, developed and validated by Flint et al. (109) at baseline, 
then 30 and 60 minutes after consumption.  
 
The VAS scales were 100 mm long with extreme ratings located at either end. The scales 
assessed hunger (0 = I have never been more hungry, 100 = I am not hungry at all), 
satisfaction (0 = I cannot eat another bite, 100 = I am completely empty), fullness (0 = Not 
full at all, 100 = totally full), prospective food consumption (0 = nothing at all, 100 = a lot), 
comfort (0 = very uncomfortable, 100 = very comfortable). A VAS for comfort level was 
added to the questionnaire as it was predicted participants might feel uncomfortable after 
consuming the large intervention servings within 10 minutes. The scales were quantified with 
a ruler, providing a value (mm) between 0 and 100. 
 
Demographic questionnaire  
At each visit participants completed a questionnaire collecting baseline information regarding 
gender, ethnicity, age, family history of gout, smoking status, medication, supplement use, 
food allergy/intolerance, diagnosis of chronic disease, disease of the digestive system and 
pregnancy. Ethnographic data was prioritised according to the Ministry of Health ethnicity 
data protocol, and participants identifying as multiple ethnicities were only represented once 
in the table (110) 
!
1.20.2 Laboratory procedures 
Whole blood glucose concentration was measured using a 5 µL spot of blood with a calibrated 
HemoCue glucose 201+ unit, at 0, 30 and 60 minutes. The first drop of blood was discarded 
by wiping it from the fingertip with lint-free gauze to prevent dilution of the blood samples 




Plasma was recovered from 500 !L sample of whole blood after centrifuging at 2000 RPM 
for five minutes. The plasma was pipetted off the supernatant and stored at -70 °C for no 
longer than four weeks until analysis. The analysis was conducted in the Human Nutrition 
Diabetes and Lipids Laboratories using a Roche Hitachi Cobas c 311 auto-analyser (Roche 
Diagnostics, Indianapolis, IN, USA). Uric acid concentration was determined by enzymatic 
colorimetric assay using a UA2 uric acid reagent test kit (Roche Diagnostics), per 
manufacturer's instructions. A two-point calibration was conducted before analysis and when 
the UA2 uric acid reagent test kit was changed. Plasma uric acid concentrations were 
expressed in µmol/L. 
 
Samples were defrosted as required and analysed in 20 sample loads. Machine consistency 
was determined using manufacturer normal and low controls, and a pooled sample. Pooled 
samples were included in the assay to measure the between-run and between-day consistency 
of the assay expressed as a coefficient of variation. The between-run coefficient of variation 
for the pooled sample, normal and high controls were 2.56%, 2.31%, and 2.72%, at mean 
concentrations of 260.8 !mol/L, 267.1 !mol/L, and 642.7 !mol/L respectively. 
 
One hundred and twenty microlitres (120 !l) of plasma was the minimum required aliquot for 
uric acid assay in the Cobas C311 analyser. When too little sample was collected, the 
available sample was diluted to 80:40, 50:50, 40:80 or a 20:100 ratio of plasma to distilled 
water. Thirty samples were diluted and corrected using the appropriate dilution factor (8.2% 
of total data). A dilution curve was calculated before sample analysis and determined to be 
linear (Appendix H). Therefore, dilution of the samples and the appropriate multiplication 
factor was taken to be an accurate method to determine the plasma uric acid concentration 




Successive uric acid concentrations were monitored for error throughout the analysis for each 
study ID. A priori, any samples that were above 410 !mol/L were re run to check validity, as 
this concentration had been predetermined as the point at which, crystallisation within the 
joints might occur in a person with gout. If previous values for that participant were also high, 
the sample was not re run. Out of all the samples run, only 1.64% of samples were re run. 
None of the re-run samples were determined to be in error, and were within ± 4% of the initial 
value. Under these circumstances, only the first assay result was used, with the second sample 
taken as was used as confirmation of an accurate first reading.  
 
1.20.3 Study outcomes 
The primary outcomes were change in plasma uric acid in response to the fructose 
concentration of the intervention foods. A secondary and separate outcome was the satiety 
response to the intervention foods.  
 
1.20.4 Raw data handling 
At recruitment participants were allocated a study identification number, which was used to 
anonymise participants during the study period. The candidate coded and entered the 
collected data into 2011 Microsoft® Excel® for Mac (Microsoft Corporation 2011TM, United 
States of America). Excel® was also used to collate and analyse baseline data. 
 
1.21 Statistical methods 
1.21.1 Sample size calculation 
Results from another study were used to estimate the sample size required for the study (111). 
Calculations for the sample size used a standard deviation of 80 !mol/L. It was determined 20 
participants were required in each test group to detect a 50 µmol/L change in plasma uric acid 





Outliers were defined as having a successive uric acid concentration increase of greater than 
100 !mol/L, and if the value in question was inconsistent with the remaining values for that 
person, the value was deemed an outlier. Four data points were removed on the basis of being 
physiologically unlikely. Two pieces of data were replaced with those participant’s baseline 
data from the second test session.  
 
1.21.3 Analysis 
Dr Jill Haszard, a biostatistician within the Human Nutrition Department conducted the 
statistical analysis in consultation with the Master of Dietetics candidate and study team. 
Statistical analyses of the data were completed using STATA/1C version 13.1 (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). The 
analysis was conducted concerning a pre-established analysis plan.  
 
1.21.4 Plasma uric acid 
Plasma uric acid response was assessed through a change in plasma uric acid from baseline at 
30 mins and 60 mins. Investigation of plasma uric acid concentration at 30 and 60 minutes 
postprandial, compared with baseline was undertaken by mixed model regression analysis, 
with time as a fixed effect and participant as a random effect.  
 
The model was adjusted for the covariates: sex, age, order of intervention (small serving 
followed by the large serving or vice versa), smoking, alcohol, family history of gout and time 
of attendance at the test session. Results are presented as mean difference and standard 
deviation (with 95% confidence intervals) within the intervention groups, and between 
servings and groups.  
 
A summary measure of the difference in plasma uric acid response between the intervention 
foods were determined by calculating the incremental area under the curve (iAUC) and are 
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presented as mean difference iAUC. Incremental area under the curve was calculated 
geometrically from baseline to 60 minutes by applying the trapezoid rule. The area above 
baseline was assigned a positive value and the area below baseline was assigned a negative 
value. The sum of the iAUC was reported. 
 
Incremental area under the curve response was analysed between small and large servings 
within groups and was investigated by modelling the change in plasma uric acid or iAUC 
against serving size, with participants as a random effect. Between-group differences were 
determined by linear regression (adjusting for baseline in analyses of mean change over time). 
 
1.21.5 Satiety 
 Analysis was undertaken to identify differences between the whole apple and apple juice 
groups to investigate differences in satiety. The mean difference was calculated in both 
analyses using regression models adjusted for baseline. Results are presented as mean change 
within the intervention groups, compared with baseline, and as the mean difference as a 





Sixty-four people were included in the analysis. Participants were between the ages of 19 and 
51 years of age. Figure 1 shows the flow of participants through the study. 
1.22 Baseline characteristics of participants  
Baseline characteristics of the participants are presented in Table 4. Participants were healthy 
adults typically in their early twenties, although two participants in the apple and apple juice 
groups were older. Participants were predominantly female, in approximately a 75:25 
(female: male) ratio, and of New Zealand European ethnicity. The majority of participants 
were within a healthy BMI range. The nine participants who reported a family history of gout 
(14.06 %) were evenly distributed across the groups.  
 
Mean baseline plasma uric acid and glucose concentrations from both testing sessions were 
averaged to produce a mean baseline concentration for each group.  Mean baseline glucose 
was within the normal range for people with normal fasting glucose (< 4.8 mmol/L) (105).   
 
There appeared to be no differences in mean baseline satiety VAS ratings before participants 



































      
Age (years)  22.3 (6.05) 24.0 (7.29) 20.9 (1.69) 22.4 (5.68) 
      
Ethnicity (%) NZ European 14 (60.87) 12 (57.14) 17 (85.00) 43 (67.19) 
 M!ori 1 (4.35) 2 (9.52) 1 (5.00) 4 (6.25) 
 Pacific Island 1 (4.35) 0 0 1 (1.56) 
 Other 7 (30.44) 7 (33.33) 2 (10.00) 16 (25.00) 
      
BMI (kg/m2)  23.5 (3.17) 22.9 (3.65) 22.6 (2.13) 23.0 (3.04) 
      
Smoking status (%) Never smoked 22 (95.7) 19 (86.4) 20 (95.2) 61 (95.3) 
 Previous 1 (4.4) 2 (9.1) 0 3 (4.7) 
 Current 0 0 0 0 
      
Family history of gout 
(%) 
 3 (4.7) 4 (6.3) 2 (3.1) 9 (14.1) 
      
Blood glucose 
concentration (mmol/L) 
 4.8 (0.4) 4.6 (0.5) 4.9 (0.6) 4.8 (0.5) 
      
Plasma uric acid 
concentration  
(µmol/L) 
 277.4 (70.1) 277.8 (65.0) 267.6 (49.1) 274.4 (62.1) 
      
Blood pressure (mm/Hg) Systolic 107.6 (11.0) 110.1 (10.4) 109.8 (10.0) 109.2 (10.3) 
 Diastolic 60.8 (6.8) 62.8 (8.7) 61.2 (5.9) 61.6 (7.2) 
      
Baseline satiety ratings Hunger 48 (26) 49 (23) 42 (20) 46 (23) 
(mm) Satiation 73 (21) 68 (19) 71 (14) 71 (18) 
 Fullness 24 (22) 24 (20) 23 (20) 23 (20) 
 Prospective food consumption 66 (23) 66 (18) 66 (15) 66 (19) 
 Comfortableness 55 (23) 64 (20) 54 (18) 58 (21) 
      
 
All participant data were used in baseline data analysis.  
All data are presented as mean (SD) unless stated otherwise 
Baseline satiety ratings were measured from fasted participants 
 
1.23 Acute plasma uric acid response  
Plasma uric acid analysis is presented as the mean difference and standard deviation, between 
baseline to 30 minutes, then 30-60 minutes within intervention groups and control in Table 2.  
!
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Incremental area under the curve (iAUC) is presented as the mean iAUC (!mol/L!h). The 
mean iAUC is a summary measure of the response to fructose between baseline and 60 
minutes and between groups (Table 6 and 7). 
 
 
Table 5. Adjusted * mean difference in plasma uric acid concentration between baseline and 30 
minutes, and 30 and 60 minutes of both large and small servings of all test foods 
 
Group Difference at 30         minutes (95 % CI) P-value 
Difference at 60 minutes 
(95 % CI) P-value 
Controls     
Glucose -5.0 (-10.9, 0.9) 0.09 -8.4 (-15.3,-1.5) 0.018 
Fructose 25.5 (11, 40) 0.01 26.3 (8.6, 44.1) 0.004 
Large Servings     
Apple 410g 18.7 (8.6, 28.8) <0.001 10.2 (3.3, 17.1) 0.004 
Juice 340mL 16.4 (9.3, 23.5) <0.001 22.9 (7.3, 38.5) 0.004 
Small Servings     
Apple 205g 8.0 (5.7, 10.9) <0.001 4.8 (0.4,9.1) 0.03 
Juice 170mL 9.4 (4.1, 14.7) 0.001 9.1 (4.5, 13.6) <0.001 
 
*Adjusted for order, hour of test, alcohol, smoking, sex and family history of gout. 
+P ! 0.05 was considered significant.  
‘Fasted or not’, was only adjusted for in second analysis. 
Apple (n = 23), Apple Juice (n = 21), Control (n = 22).  
Large servings = 410 g apple, 340 mL apple juice, 600 mL of fructose/glucose solution.  
Small servings = 205 g apple, 170 mL apple juice.  
 
 
The statistical model for the change in uric acid between baseline, 30 and 60 minutes was run 
initially without adjustment for covariates.  Subsequently, the model was adjusted for the 
covariates; time, order, alcohol, servings, smoking, family, sex and family history of gout for 
a more precise estimate of the results. These adjustments had little impact on mean estimates, 




For the iAUC analysis, unadjusted models for the difference in iAUC between the large 
servings of the intervention foods and the fructose control did not comply with assumptions 
of linearity. When adjusted for covariates, the homogeneity and normality of the residuals 
improved. As a result, only the adjusted analysis is presented in this analysis.  
 
Significant increases in plasma uric acid were observed for all of the fructose-containing test 
foods during both time periods. In contrast, glucose significantly decreased uric acid 
concentration between 30 and 60 minutes. At 60 minutes, uric acid concentration appeared to 
be maintained in the small serving of apple juice. After 60 minutes, the uric acid 
concentration appeared to halve after the small apple serving (Table 5). 
 
The rate of increase in uric acid concentration was not tested for, but it was determined by 
plotting the adjusted mean difference for each time point and foods that fructose rose steeply 
between baseline and 30 minutes. After 30 minutes the uric acid concentration tended to 
plateau (Figure 7). Apples and apple juice appeared to increase uric acid more slowly than 
pure fructose. The consumption of apples appeared to raise uric acid slower and tended to 
decline towards 60 minutes. Apple juice also appeared to increase uric acid more slowly than 
fructose and tended to increase towards 60 minutes. 
 
  
Figure 7.  Visual comparison of  the adjusted mean difference (µmol/L!h) between large servings of apple 
(410 g) and apple juice (370 mL) and fructose control between baseline and 30 minutes, and 30 and 60 
minutes.  





























1.24 Incremental area under the curve 
The adjusted difference in iAUC between the large and small servings administered to 
participants is presented in Table 6. There was a significant difference in iAUC between the 
small and large servings in both the apple and apple juice groups, and a significant difference 
existed between the glucose and fructose control beverages. The mean change in iAUC 
tended to be lower in the apple and apple juice groups, compared to the control group 
 
 
Table 6. Adjusted* difference in iAUC of small and large servings of test foods and beverages 
!
Group 
Mean iAUC of 
small serving1 
(µmol/L!h) 






95 % CI P-value + 
      
Apple  
 
311.3 713.5 412.4 18.4, 806.5 0.040 
      
Apple Juice  
 
419.6 823.9 426.8 56.1, 795.4 0.024 
      
Control  
 
-320.9 1174.2 1349.7 750.0, 1949.3 <0.001 
      
*Adjusted for order, timing, alcohol, smoking, family history of gout, and sex.  
+P ! 0.05 was considered significant.  
1 The mean iAUC of the small servings = 205 g apple, 170 mL of apple juice, and the glucose control 
beverage. 
2 The mean iAUC of the large servings = 410 g apple, 340 mL of apple juice, and the fructose control 
beverage. 
3 Mean change of iAUC between the small and large servings of each intervention group (apple = 205 g vs 
410 g, apple juice = 170 mL vs 340 mL) or control (glucose vs fructose).  
 
 
A statistical comparison of the iAUC between the large servings of the apple test foods and 














Table 7. Adjusted* difference in iAUC between large servings of apples and apple juice, compared with 
the fructose control  
!
Group Mean change iAUC (µmol/L!h) 95% CI P-value 
+ 
    
Apple  
(410 g versus fructose 
control) 
-468.1 -1346.5, 410.4 0.286 
 
 
   
Apple Juice  
(340 mL versus fructose 
control) 
-592.0 -1373.4, 189.7 0.132 
    
*Adjusted for order, timing, alcohol, smoking, family history of gout, and sex.  
+P ! 0.05 was considered significant.  
All servings contained 26.7 g of fructose.  
 
There was no significant difference between the intervention foods and control groups plasma 
uric acid response to fructose.   
 
1.25 Satiety 
Results from the VAS, assessing hunger, satisfaction, fullness, and prospective food 
consumption are presented in Table 8a and Table 8b. Each question and scale with both 
negative and positive extremes is presented in the table with the mean change in satiation 
after consumption of the test food. By using the scale beneath each question, the direction the 
mean is progressing towards can be seen. Each scale was numbered 0 to 100 mm left to right.  
 
Mean change in response from each group was calculated for each VAS. Two time periods 
were isolated between baseline and 30 minutes (first 30 minutes), and 30 and 60 minutes 
(second 30 minutes). The mean change in response to both apple and apple juice servings 






















Questions  Apple (mean change*) 
Apple Juice 
(mean change*) 
Mean difference between 
Apple and Apple juice 95 % CI P-value
+ 
How hungry do you feel?       
I have never been more hungry – I am not hungry at 
all 1
st 30 minutes 15.1 -4.1 -19.2 -39.8, 1.3 0.065 
 2nd 30 minutes -14.9 -10.7 4.2 -9.8, 18.3 0.545 
How satisfied do you feel?       
I cannot eat another bite – I am completely empty 1st 30 minutes -25.3 -2.9 22.4 7.9, 36.9 0.003 
 2nd 30 minutes 13.3 7.0 -6.4 -16.7, 4.1 0.223 
How full do you feel?       
Not at all full – Totally full 1st 30 minutes 31.5 1.7 -29.8 -46.0, -13.6 0.001 
 2nd 30 minutes -13.0 -2.1 10.9 -2.8, 24.5 0.116 
How much do you think you can eat?       
Nothing at all – A lot 1st 30 minutes -13.8 6.7 20.5 5.5, 35.6 0.009 
 2nd 30 minutes 9.9 1.4 -8.5 -17.6, 0.6 0.066 
How comfortable do you feel?       
Very uncomfortable – Very comfortable 1st 30 minutes 7.9 -1.2 -9.1 -23.6, 5.4 0.212 
 2nd 30 minutes -0.1 -1.1 -1.0 -14.3, 12.3 0.881 






 Table 8b. mean differences between large servings of whole apples and apple juice groups of questions measuring satiety 
 
+ P< 0.05 was considered significant.  
First 30 minutes refers to the difference in satiety between baseline (0 minutes) and 30 minutes, the test food was consumed after the baseline satiety questionaire 
was filled out. Second 30 minutes refers to the time between 30 and 60 minutes.  
Small serving refers to either 205 g of apple or 170 mL of apple juice. 
Large serving refers to either 405 g of apple or 340 mL of apple juice.  
*Mean change from average rating at baseline to average rating at 30 minutes, or from average rating at 30 minutes to average rating at 60 minutes. 
Apple (n = 23), Apple Juice (n = 21)  




Questions  Apple (mean change*) 
Apple Juice 
(mean change*) 
Mean difference between 
Apple and Apple juice 95 % CI P-value
+ 
How hungry do you feel?       
I have never been more hungry – I am not hungry at all 1st 30 minutes 31.1 8.4 -22.7 -39.2, -6.2 0.008 
 2nd 30 minutes -13.6 -14.1 -0.5 -15.2, 14.2 0.948 
How satisfied do you feel?       
I cannot eat another bite – I am completely empty 1st 30 minutes -51.6 -8.4 33.2 16.0, 50.4 <0.001 
 2nd 30 minutes 15.2 11.9 -3.3 -14.6, 8.1 0.560 
How full do you feel?       
Not at all full – Totally full 1st 30 minutes 49.8 20.6 -29.1 -47.1, -11.2 0.002 
 2nd 30 minutes -16.0 -14.1 1.9 -12.7, 16.6 0.789 
How much do you think you can eat?       
Nothing at all – A lot 1st 30 minutes -34.3 -4.0 30.3 15.1, 45.5 <0.001 
 2nd 30 minutes 10.3 10.1 -0.2 -11.9, 11.5 0.970 
How comfortable do you feel?       
Very uncomfortable – Very comfortable 1st 30 minutes 54.7 -5.1 -0.1 -17.3, 17.2 0.995 
 2nd 30 minutes -5.1 2.2 -1.6 -13.6, 10.5 0.796 
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There were movements in the mean satiety ratings after consumption of the apple and apple 
juice. For example, after the small serving of apple there was a tendency for hunger ratings to 
increase by 15.1 mm on the 100 mm scale towards “I am not hungry at all” (Table 8a). In 
contrast, the mean change in the apple juice group was -4.1mm in the direction of “I have 
never been more hungry”. The difference between the two foods was compared giving a 19.2 
mm separation in hunger, although in the case of the small servings of apple and apple juice, 
this did not result in a significant difference in hunger ratings (P = 0.065). 
 
During the second 30 minutes, there was a tendency for hunger ratings to shift 14.9 mm 
towards “I have never been more hungry,” after consumption of a small apple serving. The 
mean change indicates feelings of hunger were returning within 60 minutes (Table 8a). 
 
After the large serving of apple, hunger ratings decreased by  -31.1 mm on the 100 mm scale 
towards “I am not hungry at all” (Table 8b) during the first 30 minutes. The mean change in 
the large apple juice group was 8.4 mm, also in the direction of “I am not hungry at all”. The 
difference between the two foods was compared giving a -22.7 mm separation in hunger, 
which was significantly different (P < 0.001). This data indicated the apple group felt less 
hungry than the apple juice group during the first 30 minutes.  
 
The mean change in satisfaction, fullness, and prospective food consumption VAS scales 
indicated appetite decreased after consumption of the small and large servings of apple 
compared to the servings of apple juice, during the first 30 minutes. While appetite ratings 
increased after both servings of apple and apple juice at 60 minutes, the apple juice group 
tended to have greater appetite ratings. None of the participants felt uncomfortable at any time 





The primary aim of this study was to assess whether the uric acid raising potential of fructose 
differed between a fructose monosaccharide beverage and the consumption of fructose 
present in apples and apple juice. A secondary aim was to test if whole apples induced greater 
satiation than juice.  It has been suggested the natural ‘intrinsic’ fructose from fruit is as 
deleterious as added fructose (2). Others have suggested natural fructose is ‘healthier’, 
differing in its effects on blood uric acid compared to foods with ‘added’ fructose (1). 
Because of this, we expected the intervention foods (apple and apple juice) to have an 
attenuated impact on acute uric acid concentration compared to the control fructose 
monosaccharide beverage. Conversely, the intervention foods and control fructose beverage 
did not differ significantly in their effect on uric acid concentration, although all responses 
were small and transient.  
 
Our primary findings suggest the uric acid response was independent of the food providing 
the fructose dose.  Our secondary finding was that the consumption of whole apples appeared 
to cause a greater suppression of appetite compared with apple juice. Compared to the apple 
juice group, the apple group reported reduced hunger, greater satisfaction, fullness and a 
reduced desire for prospective food consumption. The tested volumes were realistic of normal 
consumption, and provide a useful evaluation of the effects of fructose containing fruit and 
fruit products on acute uric acid production and satiety. A review of current literature suggests 
the present study is the first in New Zealand to compare the acute uric acid production from 
whole apples and 100 % apple juice in realistic serving sizes as far as we are aware. 
 
Studies were previously undertaken on this topic using large doses of fructose, unrealistic of 
regular consumption (7, 15, 16).  Perez-Pozo et al. (6) fed participants 200 g fructose per day 
and observed the onset of the metabolic syndrome within a two-week period (6). The mean 
uric acid concentration rose by 65 ± 5 µmol/L (6), a much larger increase than observed in the 
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present study. Although this evidence is helpful to determine the physiological effect of 
extreme levels of fructose intake, it does not provide insight into what effects commonly 
consumed fructose amounts might induce in the general population (18). 
 
Older studies observed a moderate increase in serum uric acid after supplementation of 1 g 
per kg body weight of fructose (81). Our findings agree with the conclusions determined 
during 1970, that fructose was responsible for the increase in plasma/serum uric acid 
concentration (112, 113). A 50 g (0.67 – 0.83 g/kg) intravenous fructose dose decreased the 
ATP content of the liver to 50 % within 30 minutes post consumption, inducing a 64 μM (64 
µmol/L) uric acid rise (53). In contrast, a 0.5g/kg intravenous dose of fructose did not induce 
any significant changes in blood uric acid, suggesting a dose-response is present during 
fructose consumption (114). Consequently, 0.5 g/kg was determined a safe dose to administer 
patients in a clinical setting (114). In line with the mean weight of participants, we 
administered a mean oral dose of 0.4g/kg body weight of fructose within the present study, 
and observed a significant rise in uric acid concentration.  
 
Many human studies have investigated the antioxidant properties of apples and fruit juices (7, 
8, 15, 16, 75, 115-117); and noted an increase in the antioxidant status of participants with as 
little as 150 ml of apple juice (118). The rise in antioxidant status seen in studies that have not 
measured uric acid concentrations is suggested to be augmented by the fructose to uric acid 
reaction (8). Lotito et al. observed a 31 µM (31 µmol/L) increase in urate concentration after 
0.83g/kg fructose from five apples (63.9 ± 2.9 g) (15). Their study concluded a transient rise 
in plasma urate was common after consumption of fructose-containing food (16, 119). 
Contrary to our findings, Briviba et al. noted a 40 µmol/L increase in uric acid concentration 
after administering participants 1000 g of Golden Delicious apples (7). 
However, smaller fructose doses (36 g) have also induced a small, transient but not significant 
rise in serum uric acid at 60 minutes (16). The present study did not measure beyond 60 
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minutes post-consumption due to time restrictions, but the mean change in uric acid appeared 
to remain elevated after consumption of apple juice at the conclusion of the study period. Data 
suggests we might have observed a longer uric acid response if we had continued 
measurement until 90 minutes (8).  
 
Vieira et al. (75) administered a similar volume of apple juice to that in the present study 
using five pressed apples; without specified fructose dose (75). Apple juice consumption was 
associated with an increase in serum uric acid concentration, without a dose response to 
fructose (75).  In contrast to this recent finding, we did not observe a similar uric acid 
response after differing amounts of fructose. Instead, the change in uric acid concentration 
increased with increasing fructose administration. These results suggest a dose response effect 
with increasing consumption of fructose as seen elsewhere (120). We question the 
significance of these results to application in a clinical setting, as the transient increases 
observed were not large enough to warrant concern of hyperuricemia risk in our cohort of 
young healthy adults at low risk of gout. Rises in plasma uric acid may have been more 
significant, or clinically significant in those at risk or with gout.  
 
The benefits of whole fruits (antioxidants, potassium, fibre and other compounds) might 
outweigh the negative effects of fructose from beverages (1). Fruit juice is not recommended 
as a substitute for whole fruit intake (21, 36), despite it being viewed by many as a healthy 
alternative to sugar-sweetened beverages.  A large cohort study recently found no association 
with fruit and the risk of gout (3). The Ministry of Health predicts sugary non-alcoholic 
beverages (including fruit juice) provide 26% and 29% of the total sugar consumed by New 
Zealand children and adults respectively (43, 66), whereas fruit only comprised 13 % 




1.26 Satiation  
A secondary finding was whole apples stimulated greater satiety and slower appetite return 
than apple juice. Studies that observed this result also determined the rate of ingestion 
increased when fruit juice was consumed (22, 23, 25, 103, 121, 122) and less satiation 
occurred compared to whole fruit (23, 25). There is evidence that energy from liquid sources 
is less satiating and is not well compensated for by eating less at successive meals (24, 123). 
Mattes suggests this is due to the lack of gastric distension, decreased transit time, and the 
body’s lack of detection of calories from liquids (93). Although not all studies have observed 
a difference between solid and liquid versions of foods (91, 124) 
 
Matching the energy and fibre contents between the intervention foods was not possible in the 
present study. An increase in fibre and energy present in test foods, particularly the whole 
apple is suggested to increase satiety (22, 23). Yet it was noted when the fibre contents of 
both liquid and solid test foods were matched; there were no significant differences between 
satiety rating (25). Pectin fibre from a sweetened beverage repressed appetite and ghrelin 
secretion, but did not decrease successive food consumption (122), compared to pectin fibres 
consumed from solid fruit (122). We matched fructose content between test foods; therefore, 
these findings are novel as the effects on satiety of foods matched for natural fructose content 
has not been considered in previous literature. 
 
We used cloudy apple juice with the fibre content retained, although mechanically disrupted 
(106). The average dietary fibre content of whole raw apple is 2.1 g per 100 g (73), compared 
to 0.3 g per 100 g in the commercial apple juice (106). We did not compare the satiating 
properties of the intervention foods to the fructose monosaccharide; thus, the effect of fibre 
cannot be ruled out in changes observed in satiation, due to the difference in fibre content. 
The fructose monosaccharide is also suggested to decrease satiety (41), as it was noted that 
fructose does not induce the same hormonal regulatory effects as glucose (41). Because we 
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matched the fructose concentrations between the foods, it could be expected that the volume 
of food or fibre had the greatest effects.  
 
The solid structure of food may be the main contributing factor to increased satiety, as solid 
meals are noted to induce different physiological responses when compared to a homogenised 
form (103). It is suggested solid foods increase cephalic phase, stomach distension and 
mechanical stimulus, as they are of a larger food particle size (103). However, when weight, 
fibre and energy content were matched, the volume of the whole apple was noted as larger 
(25). The due to the solid structure of fruit, the cell wall is likely to increase chewing quantity 
(23), which was noted to increase the length of the cephalic phase during digestion (125-127). 
An increased cephalic phase may induce a longer satiety response (125). Accordingly, it has 
been determined as difficult to separate the effects of the solid structure of the food from the 
effect of fibre from the same food on satiety in previous studies (22). 
1.27 Strength and limitations  
The serving sizes used in this study strengthen its relevance to dietary practice. The amounts 
we provided were below (small serving) and above (large serving) the recommended servings 
of fruit per day in New Zealand (42), equating to approximately 1.6 and 3.2 apples. The 
recommended serving size on the nutrition information panel of the apple juice used was 200 
mL, however; we provided participants 170 mL and 340 mL servings. Two hundred 
millilitres is less than a standard cup size; thus it is likely consumers would consume more 
than the recommended serving size. Therefore, the servings administered in the present trial 
were likely to be realistic. In the current study, no participants struggled to consume the 
serving amounts of juice.  
 
We used a positive and a negative control. Our positive control was used to note the effects of 
the fructose monosaccharide without other effect from other food components. In the 
monosaccharide form, it does not require further digestion before absorption takes place 
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(107); thus, quick absorption was predicted. Glucose was used as a negative control, as there 
is no evidence pointing towards glucose being involved in uric acid metabolism (53, 108). 
Consequently, we did not expect to see an increase in uric acid after consumption of the 
glucose. Other strengths include participant compliance with pre-test requirements, 
consistency during blood measurements, accurate timing methods, and few missing data. 
 
There are limitations to this study. The inability to blind participants to which intervention 
they were receiving was a limitation. A further limitation originates from the use of a cohort 
selected from predominantly female New Zealand European university students, enrolled in 
nutrition papers. In contrast, gout is more likely to occur in older men (14, 86-88); thus it is 
unknown how applicable these findings are to the metabolically at risk population. Previous 
studies have suggested the risk of gout is also linked to the presence of several genes common 
in M!ori and Pacific (30). As the study population had only a small proportion of M!ori (6 %) 
and Pacific (2 %) we did not have the power to measure any differences in uric acid response 
between ethnicity. 
 
Although VAS are a valid measurement tool (128), satiety is a subjective perception (22) 
perhaps limiting reliability. We measured satiety through the VAS method and did not adjust 
for any covariates or test ad libitum consumption, which is often used in satiety studies (128). 
Confounders to these satiety measurements are likely to be the differing energy content, mass 
and fibre content of the apples and apple juice, as apples are fibrous, “energy dilute” foods in 
comparison to apple juice (36).  
 
Lastly, discrepancies exist between the mean difference of uric acid (Table 5) and the iAUC 
data (Table 6 and 7). Data outliers in the control group were not removed without valid 
justification (Table 7), and are the likely cause. The results from these participants might be 
outliers due to flawed methodology or might be legitimate results. These people might be 
representative of a small component of the population who are be susceptible to the effects of 
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fructose on uric acid, which our sample size was too small to detect. As we had a small 
sample and outliers present, the distribution is likely moved away from the true mean, 
skewing the data.  
1.28 Conclusions and recommendations 
Gout is an important health issue for New Zealanders, particularly in those of Pacific or M!ori 
descent and is increasing in prevalence (13, 31). We noted a significant, but not clinically 
significant increase in uric acid in a cohort of young university students. The rise in uric acid 
was transient and not likely to induce negative consequences in our cohort. What effect 
natural fructose would have on uric acid concentration in an older population with greater 
genetic or ethnic susceptibility (86), we cannot provide comment. We determined no 
difference in uric acid response to fructose from natural sources in realistic serving sizes when 
compared with a monosaccharide beverage. Whole apples were determined to be more 
satiating than apple juice in this cohort of healthy young New Zealanders. This study provides 
further evidence for consumption of whole fruit rather than fruit juice. 
 
We recommend further investigation into the difference between natural versus added 
fructose in an older population. As our cohort were predominantly female university students, 
the results of this study cannot be generalised to other subpopulations, which might be at 
greater risk of gout (14, 86). A similar study could be conducted with a greater cohort of 
M!ori and Pacific peoples and people of more advanced age, with consideration to the known 








Implications to dietetic practice  
!
Although we observed a significant increase in plasma uric acid concentration in this 
randomised controlled crossover trial, the implications of these results may bear little clinical 
significance. The participants were typically healthy students in their early twenties, who 
were not at risk of gout. Whether the current study has relevance to populations who more 
metabolically at risk of gout is undetermined. More evidence is required to broadly apply 
these results to the larger or more ethically diverse demographic, which might be seen in 
dietetic practice.  
 
The popular idea that natural fructose behaves in a different manner in the body was 
determined to be a misconception in the present study. No statistical difference was observed 
between the effects of a fructose control beverage, whole apple or apple juice on plasma uric 
acid concentration. The increase in uric acid was dependent on the dose of fructose, not the 
food or beverage form.  
 
We observed a small transient rise in plasma uric acid concentration. For a young, healthy 
weight population there was no suggestion this dose–response is of pathological concern. 
Although fruit contains fructose, it is still a low energy; high nutrient dense appropriate food 
(42), which has beneficial effects as a source of fibre, vitamins and satiation within the diet. 
Many foods have been determined to induce gout attacks including meat, seafood and some 
alcohol (84, 129). However, fruit has not been observed to induce gout attacks as far as we are 
aware. Accordingly, the risks and benefits need to be weighed up when considering what 
foods to include and exclude for the dietary management of gout. The restriction of foods 
should be considered on an individual basis.  
 
The dietetic message surrounding the intake of sugary beverages including fruit drinks should 
not change. It is best to choose 100% fruit juice without added sugar. However, fruit juices 
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contain similar nutrients present in the whole fruit, but may contribute more energy, less fibre 
and other favourable components i.e. antioxidant properties as whole fruit (21, 130). We have 
observed further evidence supporting existing recommendation that whole fruit induces 
greater satiation than apple juice, providing greater evidence for whole fruit consumption to 
be encouraged over fruit juices (36). Benefits such as increased fibre and effects on satiety 
antioxidants and phenolic compounds and vitamins need to be considered in the context of 
whole fruit in the diet, not solely as a source of fructose. Carbohydrates in a liquid matrix are 
not as well compensated as solid forms, at subsequent meals; which may promote positive 
energy balance and weight gain (24). The consumption of fruit juice might lead to a greater 
energy intake, as one glass has greater calories without the benefits of dietary fibre compared 
to fruit (21, 130). It is suggested there is no dietary requirement for fruit juice consumption 
(21, 131), as whole fruit provide a better balance of energy and satiation (21, 131). 
 
An aim of incorporating more satiating foods including fruit and vegetables into the diet is to 
induce weight loss. The consumption of satiating foods is correlated with reduced energy 
intake (132, 133). Strategies to avoid obesity set by the World Health Organization include 
promoting fruit and vegetable intake and restricting intake of energy dense foods (36). 
Increasing the intake of "energy dilute" foods including fruits, could decrease total energy 
intake and increase micronutrient intake (1, 36), but also reduce the risk of disease associated 
with obesity and its related co-morbidities (1).  
 
Dietitians need to be aware of the misconception some patients might hold; that free fructose 
that from natural sources is treated differently in the body, and to promote fruit intake. 
Educating patients about the benefits of fruit consumption, including key nutrients and a 
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UNIVERSITY OF OTAGO HUMAN ETHICS COMMITTEE 
APPLICATION FORM: CATEGORY A 




1. University of Otago staff member responsible for project:  
Surname First Name Title   





3. Contact details of staff member responsible (always include your email address): 
bernard.venn@otago.ac.nz 
Tel 03 479 5068 
 
4. Title of project: HUNT311 clinical nutritional laboratory; a repeated teaching activity 
 
5. Indicate project type and names of other investigators and students:  
 
 




Student Researchers        Names:  














6. Is this a repeated class teaching activity?  
















If YES and this application is to continue a previously approved repeated class teaching activity, 
provide Reference Number: 13/022 
 
 
7. Fast-Track procedure (Delete answer that does not apply) 
 








8. When will recruitment and data collection commence? 
 February 2015 
 




9. Funding of project 
 Is the project to be funded by an external grant? 
 NO 
 
 If YES, specify who is funding the project: 
 
 
 If commercial use will be made of the data, will potential participants 




10. Brief description in lay terms of the purpose of the project (approx. 75 words): 
 
 The purpose of the HUNT311 laboratories is for students to experience participation in a 
clinical nutritional trial. Measured outcomes will be changes in blood glucose, feelings of hunger, 
and serum uric acid concentrations in response to consuming various carbohydrate containing 
foods. The laboratory will be a source of individual and group data to be used in a class 
assignment with potential for publication using anonymous group data. Genetic data will be 
collected to investigate the interaction between genotype and diet in determining serum uric acid 
and glucose concentrations – this information will be analysed by Human Nutrition MDiet 
students.  
 
11. Aim and description of project  
 
The aim of this laboratory is to test the glycaemic, satiating and uric acid raising potential of 
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carbohydrate containing foods. This information will be used by HUNT311 students as a 
learning exercise and in the writing of his or her assignment. A secondary (non-teaching) aim 
is to investigate the interaction between genetic variants and dietary exposure in determining 
serum uric acid and glucose response. One existing example of this is non-additive interaction 
between the GLUT9 gene and sugar-sweetened beverage consumption in determining serum 
urate levels (Batt et al. 2013). This work will replicate published interactions with the 
potential to discover novel interactions.  
 
Batt et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with 
SLC2A9 genotype specific effects on serum urate and risk of gout. Ann Rheum Dis 2013;!doi: 
10.1136/annrheumdis-2013-203600. [Epub ahead of print] 
 
12. Researcher/instructor experience and qualifications in this research area  
 
Dr. Venn is experienced in conducting research trials involving human participants. 
Testing will be carried out according to our standard procedure in the Department of 
Human Nutrition Undergraduate Laboratories. A/Prof Merriman has extensive experience in 
researching genetics of metabolic disease, including environmental interactions. 
 
13. Participants   
13(a) Population from which participants are drawn: Human Nutrition students 
13(b) Inclusion and exclusion criteria:  
Inclusion: men and women in the age range of 18 – 60 y, inclusive. 
Exclusion: People diagnosed with chronic disease including diabetes mellitus, 
cardiovascular disease, cancer, and diseases of the digestive system; that suffer from 
food allergies; and women who are pregnant. 
13(c) Estimated number of participants: All HUNT311 students (currently 
100+) 
13(d) Age range of participants: 18-60y 
13(e) Method of recruitment: Recruitment will be by invitation to the 
students by email and in class at the University of Otago. 
13(f) Specify and justify any payment or reward to be offered  
 No payment or reward 
 
14. Methods and Procedures:  
 
The purpose and scope of the laboratory will be discussed in class. An Information Sheet (attached) 
will be given to students and teaching and research staff will be available to answer questions 
regarding the study. If students are willing to continue, a consent form (attached) will be given to 
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them. Participants will have their height and weight measured in a screened-off area to ensure the 
participants privacy. A questionnaire will be administered to ensure that eligibility criteria are met 
and for collection of demographic data. Test foods will be provided to participants. In 2015, the foods 
will be supermarket-purchased sugary beverages and whole fruit. 
 
For measuring blood glucose and serum uric acid, capillary blood is collected by finger 
pricking using a sterilised disposable lancet. During each test, a series of eight blood samples 
are collected over a period of three hours following the consumption of the food. Each student 
will test two foods, each on a separate non-consecutive day. The Department of Human 
Nutrition will use trained personnel to do the finger pricking. Students will attend the 
laboratory after an overnight fast of at least 10 hours. On the evenings preceding each of these 
test days, participants will be advised not to exercise and to ensure that their evening meal 
contains a carbohydrate-rich food. On each of the test days, two finger-prick blood samples 
will be taken five minutes apart as a baseline blood glucose concentration. This method of 
collecting blood for analysis causes minimal discomfort to the participant. Blood glucose 
concentrations will be determined from a drop of blood using a Hemocue Glucose 201 
Analyzer. Following this, a test food will be consumed over a fifteen minute period and a 
series of six more finger-pricks will be undertaken at 15, 30, 45, 60, 90 and 120 min. In the 
event of an abnormal result, a repeat fingerprick may be required. Adhesive plasters will be 
provided to hold in place a cotton wool swab covering the small incision. The total volume of 
blood extracted from the finger-pricks will be less than two millilitres. There is no excess 
blood for disposal. During this laboratory, students will also be given a set of questions 
regarding how hungry they feel as a measure of satiety. Blood pressure will be taken at 
baseline and one hour after consumption of the test food in accordance with the Department of 
Human Nutrition good clinical practice guidelines using an OMRON digital blood pressure 
monitor. If the average of three systolic blood pressure readings is less than 100 or greater 
than 140 mmHg, the student will proceed with the laboratory and will be advised to consult 
his or her healthcare provider. 
 
For the genetic analysis, DNA will be extracted from a 10 ml saliva sample using a 
commercially available kit. The DNA will be quantitated, diluted to a standard concentration 
and genotyped for selected genetic variants using the Taqman genotyping system. Interaction 
between genotype and dietary exposure will be determined using linear regression in a 





15. Compliance with The Privacy Act 1993 and the Health Information Privacy Code 1994 
imposes strict requirements concerning the collection, use and disclosure of personal 
information.   
 
The questions below allow the Committee to assess compliance. 
 
15(a) Are you collecting and storing personal information (e.g.name, contact 
details, designation, position etc) directly from the individual concerned that 
could identify the individual? (Delete the answer that does not apply.) 
YES  
 
15(b) Are you collecting information about individuals from another source?  
NO 
 
If YES, explain: 
 
15(c) Collecting Personal Information (Delete the answer that does not apply): 
• Will you be collecting personal information (e.g. name, contact details, 
position, company, anything that could identify the individual)? 
 YES  
• Will you inform participants of the purpose for which you are 
collecting the information and the uses you propose to make of it? 
 YES  
• Will you inform participants of who will receive the information? 
 YES  
• Will you inform participants of the consequences, if any, of not 
supplying the information? 
 YES  
• Will you inform participants of their rights of access to and correction 
of personal information? 
 YES  
 
 Where the answer is YES, make sure the information is included in the Information 
Sheet for Participants. 
 
 If you are NOT informing them of the points above, please explain why: 
 
 
15(d) Outline your data storage, security procedures and length of time data 
will be kept  
 
The information will remain confidential to the study investigators. Paper copies will 
be kept in a lockable office and electronic data stored on departmental computers in 
password protected files. The results of this study may be published but no individual's 
identity will be revealed. At the end of the project any personal information will be 
destroyed immediately except that, as required by the University's research policy, any 
raw data on which the results of the project depend will be retained in secure storage 




15(e) Who will have access to personal information, under what conditions, and 
subject to what safeguards? If you are obtaining information from another 
source, include details of how this will be accessed and include written permission 
if appropriate.  Will participants have access to the information they have 
provided? 
Only Dr Bemard Venn will have permanent access to the personal information. Paper 
copies will be stored in Dr Venn's University of Otago office and any information 
transferred into digital form will be stored on Dr Venn's University computer. If a 
nominated postgraduate student enters data, this will only be done on a desktop 
university password-protected computer. At the completion of data entry, the student 
will be asked to transfer the electronic file to Dr Bemard Venn and to delete the file 
from the student computer. 
Statistical analysis will be done using anonymous data. 
 




 If YES, specify in what form you intend to do this: 
 
15(g) Do you propose to collect demographic information to describe your 




15 (h) Have you, or will you, undertake M!ori consultation? Choose one of the 
options below, and delete the option that does not apply: 
 (Refer to http://www.otago.ac.nz/research/maoriconsultation/index.html). 
 
NO If not, provide a brief outline of your reasons (e.g. the research is being 
undertaken overseas): 
YES We have completed the University of Otago online M!ori consultation 
form attached (pages 14-15). It is scheduled for discussion at the Ng!i 





16. Does the research or teaching project involve any form of deception?   
NO 
  
If yes, explain all debriefing procedures: 
 
 
17. Disclose and discuss any potential problems or ethical considerations: (For example: 
medical or legal problems, issues with disclosure, conflict of interest, safety of the researcher, etc.  
Note: if the student researcher will be travelling overseas to undertake the research, refer to item 12 
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of the Filling Out Your Human Ethics Application document.  Please note that approval from the 
Human Ethics Committee does not override the University of Otago’s Field Policy and Travel Policy, 
which must be complied with.) 
 
This is a repeated teaching activity and research students may be involved in data collection and 
analysis from year to year. The research students will only work with data with the University of 
Otago student ID as an identifier, rather than student names.  
There may be some discomfort from finger pricking 
 
 
18. *Applicant's Signature:   .............................................................................   
 Name (please print): ………………………………………………………. 
 Date:  ................................ 
 *The signatory should be the staff member detailed at Question 1. 
 
 
19. Departmental approval:  I have read this application and believe it to be valid research and 
ethically sound.  I approve the research design.  The Research proposed in this application is 
compatible with the University of Otago policies and I give my consent for the application to be 
forwarded to the University of Otago Human Ethics Committee with my recommendation that it be 
approved. 
Signature of **Head of Department: .......................................................................... 
 Name of HOD (please print): ………………………………………………………. 
  Date: ..................................................... 
**Where the Head of Department is also the Applicant, then an appropriate senior staff member must 








HUNT311 clinical nutritional laboratory; a repeated teaching activity  
INFORMATION SHEET FOR PARTICIPANTS  
Thank you for showing an interest in this project. Please read this information sheet carefully 
before deciding whether or not to participate. If you decide to participate we thank you. If you 
decide not to take part there will be no disadvantage to you and we thank you for considering our 
request.  
What is the Aim of the Project?  
The aim of this study is to test the glycaemic, satiating properties and uric acid raising potential of 
carbohydrate containing foods. This requires attending the laboratory on two occasions. You and 
other HUNT311 students will use the information in the writing of a HUNT311 assignment. If 
you choose not to participate, you will still be required to attend the laboratory to observe and 
data will be provided to you; the assessment of your assignment will in no way be affected.  
What Type of Participants are being sought?  
HUNT311 students with no diagnosis of diabetes mellitus, cardiovascular disease, cancer, 
diseases of the digestive system; you are not pregnant, you do not suffer from food allergies or 
take medication that affects glucose absorption and metabolism 
What will Participants be Asked to Do?  
Main laboratory experiment 
 
You will be asked to attend the Department of Human Nutrition Undergraduate Laboratory on 
two occasions, separated by one or two weeks apart, as you will be testing two different amounts 
of fruits or beverages. If eligibility criteria are met, you will be asked to read and sign a consent 
form, we will collect some personal information from you comprising demographics, height and 
weight. Following this, the first test will be conducted. Testing is conducted in the morning with a 
start time of between 7 -8 am. You will be required to fast, ie: to have no food, no sugar-
sweetened chewing gum or drinks except water after 10 pm on the night before the test. We 
would prefer that you did not walk to the University. If you do walk or cycle we would like you 
to arrive 20 minutes early so that your heart rate and blood glucose have a chance to settle down 
before you start the test. On arrival your blood pressure will be taken following which two finger-
prick blood samples will be taken in the fasting state using a single-use disposable lancet 
designed to minimize discomfort. You will then be given a test food or beverage to consume. 
After this, additional finger-prick blood samples will be taken at 15,30,45,60,90, and 120 min. 
The fingerpricks may cause some discomfort. In the event of an abnormal result, a repeat finger-
prick may be required. The total volume of blood collected will amount to less than half a 
teaspoon. During this three hours we would like you to remain seated in the room with the 
exception of toilet visits if necessary. You are free to read or talk. At the end of three hours there 
will be some food for you to eat on the premises or to take away.  
 
Genotyping uric acid and glucose genes 
You will be asked to donate a saliva sample from which DNA will be prepared. This will be used 
to investigate how genes involved in regulating serum uric acid and glucose levels interact with 
diet in their regulation of uric acid and glucose levels. This research will not be part of your 
laboratory, but will contribute to the research projects of Masters of Dietetics students within the 
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Department of Human Nutrition. Please note: you will not be required to write up this aspect of 
the laboratory. If you agree to take part we will advise you of your genotype for the glucose and 
uric acid transporter GLUT9. 
What Data or Information will be Collected and What Use will be Made of it?  
For the main laboratory exercise we will collect data on your age, ethnicity, smoking habits and 
gender and we will be measuring your height and weight. The purpose of collecting this 
information is to describe the overall characteristics of the study population. We will also ask you 
to fill in a medical questionnaire to ensure you meet the study eligibility criteria. From your blood 
samples we will be testing glucose and uric acid concentration. The information will remain 
confidential to the study investigators. Paper copies will be kept in a lockable office and 
electronic data stored on a departmental computer. The results of the project will be pooled and 
may be published and available in the University of Otago Library (Dunedin, New Zealand) but 
every attempt will be made to preserve your anonymity. The data and samples collected will be 
securely stored in such a way that only those mentioned below will be able to gain access to it. 
Data and samples obtained as a result of the research will be retained for at least 5 years in secure 
storage. Any personal information held on the participants such as contact details may be 
destroyed at the completion of the research even though the data and samples derived from the 
research will, in most cases, be kept for much longer or possibly indefinitely. If you choose not to 
supply information this may exclude you from taking part in the study. You have rights of access 
to the personal information that you have given to us and you may correct or change this 
information.  
For the genetic testing, we will genotype your GLUT9 gene to investigate the interaction 
between this genetic variant and dietary exposure in determining serum uric acid and glucose 
response.  
Interaction between gene variants and dietary exposure is an emerging field and we would 
like to retain your DNA if new gene interactions are found relating to serum uric acid and 
glucose response. 
Testing blood glucose has the potential to reveal whether a person has diabetes or is at risk of 
pre-diabetes. If elevated blood glucose concentrations are found, you will be advised to make 
an appointment with student health or with your general practitioner. If the average of three 
systolic blood pressure readings is less than 100 or greater than 140 mmHg, you will be able 
to proceed with the laboratory but we will advise you to consult your healthcare provider. 
Can Participants Change their Mind and Withdraw from the Project?  
You may withdraw from participation in the project at any time and without any disadvantage to 
yourself or to your HUNT311 assessment of any kind.  
What if Participants have any Questions?  
If you have any questions about our project, either now or in the future, please contact - 
Dr Bernard Venn; Department of Human Nutrition 
Telephone: 03 479 5068 email bernard.venn@otago.ac.nz 
Associate Professor Tony Merriman; Department of Biochemistry 
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Telephone: 03 479 5798 email tony.merriman@otago.ac.nz 
This study has been approved by the University of Otago Human Ethics Committee. If you have any 
concerns about the ethical conduct of the research you may contact the Committee through the Human 
Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be treated in confidence 






HUNT311 clinical nutritional laboratory; a repeated teaching activity  
 
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet and understand the procedures. All my questions have  
been answered to my satisfaction. I understand that I am free to request further information  
at any stage.  
 
I know that: 
1. My participation in the project is entirely voluntary;  
2. I am free to withdraw from the project at any time without any disadvantage to myself or to 
my HUNT311 assessment;  
3. Personal identifying information will be destroyed at the conclusion of the project but any raw 
data on which the results of the project depend will be retained in secure storage for at least 
five years;  
4. Fingerprick blood sampling may cause some discomfort.  
5. The results of the project may be published and will be available in the University of Otago 
Library (Dunedin, New Zealand), but every attempt will be made to preserve my anonymity 
 
I consent to attending the laboratory on two days following an overnight fast, consuming the study food and 
providing eight blood samples obtained by finger pricking over three hours on each test day 
 
      Yes ! / No  
 
I consent to providing a saliva sample for genotyping 
 
      Yes ! / No  
 
I consent to storage of my saliva sample for future genotyping relating to uric acid and glucose 
metabolism 
Yes ! / No  
 
 
Name ........................................... Signature................................................. . Date ........................ . 
This study has been approved by the University of Otago Human Ethics Committee. If you have 
any concerns about the ethical conduct of the research you may contact the Committee through 
the Human Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be 
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Appendix C  
 
Cawthron Laboratory certificates of analysis 


















1.29 Communication strategy: 
Two weeks before: 
Black board: Have Information sheet, lab timetable and ethical consent form available 
on Black board.  
One week before: 
Email from Andrew once students are enrolled and streamed:  – lab streams, 
information sheet, pre-lab instructions and contact details if they have a time table 
clash. 
Day before first test session: 
In lectures with Bernard Venn, Thursday before first test session: verbal reminder to 
attend and pre-lab instructions. 
Day of test session: 
At test session: Ethics consent form, information sheet and fill-in form for self-








1.30 Blood Collection protocol  
 
1. Greet participant 
2. Explain that you’ll be taking a sample and ask them if you need their cooperation to 
encourage blood flow, drop hand down, etc. 
3. Ensure you use one of the middle three fingers that have had a wheat bag applied. 
4. Alcohol swab the finger. 
5. Prick with lancet and use the square gauze wipe to quickly clear away the initial 
blood, to prevent alcohol dilution of blood.  
6. Collect sample into BD Microtainers – aim for at least 375 !L (halfway between 250 
!L and 500 !L marker).  
7. Apply the very tip of micro cuvette to a drop of blood. Wipe the outside of the micro 
cuvette with the square gauze wipe and place in the HemoCue glucose 201+ unit. 
8. Invert mini tube with the lid on 7-9 times so that the blood mixes with the K2EDTA 
anti-coagulant coating inside the tube. 
9. Give participant cotton swab or bandaid and ask them to apply pressure.  
10. Place BD Microtainers for uric acid assay in chilli-bin 
11. Ensure participant records the blood glucose concentration on their data collection 
form. 
Additional notes: 
Use saline to clean the area to minimise clotting.  
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1.31 Dilution curve 
 
 
Figure 8. The correlation between uric acid concentration and the percentage of control Path was 
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